Beryl Drugs Share Price Today | Stock Price & Beryl Drugs Share Screener
As of October 5, 2026, the live Beryl Drugs share price (BSE: BERLDRG) is ₹24.84, down 1.78% from the previous close, with shares trading between ₹23.12 and ₹25.69 in today's trading session, and a 52-week range of ₹16.87–₹25.65. Check BERLDRG 52-week chart for the annual price range and momentum. Use the Beryl Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Beryl Drugs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹22 and net income of ₹1, with EBITDA of ₹2, an operating margin of 8.0% and a profit margin of 4.6%.
Beryl Drugs Share Price Chart
Track the current stock price of Beryl Drugs with an interactive chart. Analyse BERLDRG share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Beryl Drugs stock quote in one place.
The quote of ₹24.84 sits between the 52-week low of ₹16.87 and the 52-week high of ₹25.65, and the latest session moved -1.78% from the previous close.
Beryl Drugs Company Profile - Fundamental Screener
Screen Beryl Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BERLDRG shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE415H01017.
Company Details
Classification
Identifiers and Leadership
Beryl Drugs Balance Sheet Screener
Screen BERLDRG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹15, down from ₹16 in 2025.
Latest statistics put total assets at ₹15 and shareholder funds at ₹10, with a leverage ratio of 0.34.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 15 | 16 | 18 | 18 | 18 | 19 | 17 | 15 | 11 | 10 |
| Current Assets | 7 | 9 | 10 | 10 | 11 | 10 | 8 | 5 | 7 | 7 |
| Fixed Assets | 7 | 6 | 6 | 6 | 6 | 8 | 9 | 2 | 2 | 2 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 10 | 10 | 9 | 8 | 7 | 8 | 8 | 8 | 7 | 6 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 5 | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 1 |
Beryl Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Beryl Drugs income statement and profit fundamentals. Analyze BERLDRG quarterly results. Beryl Drugs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹22 and net profit was ₹1, equal to earnings per unit of ₹1.20, at an operating margin of 8%.
In that period expenses were ₹20, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹19 and net profit of ₹0.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 22 | 19 | 23 | 27 | 27 | 15 | 14 | 13 | 13 | 16 | 11 | 14 | 14 |
| Expenses | 20 | 17 | 20 | 25 | 25 | 14 | 13 | 12 | 12 | 14 | 11 | 13 | 13 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | 1 |
| Operating Profit % | 8.00% | 10.00% | 6.00% | 9.00% | 7.00% | 3.00% | 10.00% | 7.00% | 8.00% | 7.00% | -1.00% | 4.00% | 6.00% |
| Depreciation | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| EPS | 1.20 | 0.84 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | 1.16 | 1.96 | -0.88 | 0.33 | 0.17 |
Beryl Drugs Cash Flow Screener - Liquidity Fundamentals
Screen BERLDRG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹4, and net cash flow was an outflow of ₹1.
Over the same period, investing activities used ₹2 and financing activities used ₹2.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 4 | 3 | 1 | 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| Investing Activities | -2 | -1 | -1 | -1 | 1 | 0 | -2 | -5 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | -2 | -2 | 0 | -1 | 0 | -1 | 2 | 2 | 0 | 0 |
| Net Cash Flow | -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 |
Beryl Drugs Shareholding Pattern Screener
See Beryl Drugs shareholding pattern with promoter, FII, and DII holdings. Check Beryl Drugs promoter holding and ownership changes for BERLDRG on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 27.48%, foreign institutions 0.00%, domestic institutions 0.00% and the public 64.94%, spread across 7,349 shareholders.
The shareholder count was 7,349 in 2026-Mar, compared with 7,309 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 27.48% | 27.82% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 64.94% | 63.56% | 68.53% | 68.69% | 68.71% | 66.25% | 66.26% | 68.06% |
| Other Holding | 7.59% | 8.62% | 5.08% | 4.93% | 4.91% | 7.37% | 7.35% | 5.55% |
| Shareholder Count | 7,349 | 7,309 | 7,431 | 7,415 | 7,446 | 7,409 | 7,257 | 7,325 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Beryl Drugs. Beryl Drugs dividend yield can be compared with peers and other stocks in the market.
Beryl Drugs Stock Index Membership - Nifty & Sensex
See which indices include Beryl Drugs stock. Check BERLDRG index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Beryl Drugs Market Events Screener - Corporate Actions
Get Beryl Drugs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Beryl Drugs stock events that may affect BERLDRG share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 29, 2026, with a record date of September 29, 2026.
It is followed by Quarterly Result Announcement dated August 11, 2026 and Quarterly Result Announcement dated May 28, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-29 | 2026-09-29 | Annual General Meeting | NA | -2.13% |
| 2026-08-11 | 2026-08-11 | Quarterly Result Announcement | NA | 8.77% |
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | -1.24% |
| 2026-05-11 | 2026-05-11 | Extraordinary General Meeting | NA | 6.79% |
| 2026-03-16 | 2026-03-16 | Extraordinary General Meeting | NA | -6.91% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -1.32% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 1.70% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -16.04% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -3.22% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -4.64% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | -6.59% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 0.30% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -1.84% |
Beryl Drugs Competitors Screener - Peer Stocks Comparison
Screen BERLDRG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Beryl Drugs Company Announcements - News & Reports Screener
Screen BERLDRG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 2, 2026 and October 1, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Closure of Trading Window | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING HELD ON 29TH SEPTEMBER 2026 | - |
| 2026-10-01 | Approval For Increase In The Limit Of Material Related Party Transactions With M/S. Aminova Infusions Pvt. Ltd. | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-03 | Reg. 34 (1) Annual Report. | - |
| 2026-09-03 | 33RD ANNUAL GENERAL MEETING NOTICE TO BE HELD ON 29TH SEPTEMBER 2026 AT 11 A.M. AT KANCHAN PALACE COMMUNITY HAII NIPANIA RING ROAD INDORE | - |
| 2026-09-03 | EVOTING DATE FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING | - |
| 2026-09-03 | RECORD DATE FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING | - |
| 2026-09-02 | ANNUAL BOOK CLOSURE | - |
| 2026-09-02 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-08-27 | Board Meeting Intimation for Approve Board Report And Other Matters Related To 33Rd Annual General Meeting Of The Company | - |
| 2026-08-20 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-11 | UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 | - |
| 2026-08-11 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-08-05 | Board Meeting Intimation for Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-07-21 | Intimation Regarding Temporary Unavailability Of The Companys Website Due To An Unexpected Technical Issue | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹24.84, within a 52-week range of ₹16.87 to ₹25.65. The P/E ratio is 20.85 and the P/B ratio is 1.32, with earnings per unit of ₹0.84. Market capitalisation stands at ₹13.16 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.